10-Q: Quarterly report

SECNov 9 05:07 · Announcements

10-Q/A: Quarterly report (Amendment)

SECSep 24 04:59 · Announcements

10-K/A: Annual report (Amendment)

SECSep 24 04:59 · Announcements

10-Q: Q2 2024 Earnings Report

SECAug 10 04:03 · Announcements

Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?

Yahoo FinanceJun 25 00:06

10-Q: Q1 2024 Earnings Report

SECMay 11 04:12 · Announcements

Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

Yahoo FinanceFeb 13 22:00

Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

BenzingaJan 25 22:00

Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024

Yahoo FinanceJan 23 22:00

Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress

GlobeNewswireAug 16, 2022 05:35

Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering

GlobeNewswireJul 29, 2022 23:50

Revelation Biosciences stock slides 47% on pricing $5M securities offering

Seeking AlphaJul 26, 2022 20:37

Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering

GlobeNewswireJul 26, 2022 20:21

Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

GlobeNewswireJul 23, 2022 06:35

Revelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

GlobeNewswireJul 14, 2022 21:05

Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis

GlobeNewswireMay 23, 2022 21:01

Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate Progress

GlobeNewswireMay 17, 2022 04:10

Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate Update

GlobeNewswireApr 6, 2022 21:08

Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection

GlobeNewswireMar 30, 2022 21:13

Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza Infection

GlobeNewswireMar 24, 2022 21:08